AstraZeneca deals take CRISPR to its drug discovery heart
This article was originally published in Scrip
Executive Summary
AstraZeneca has leveraged its "open-innovation" approach to strike four deals in the ground-breaking CRISPR genome editing field, positioning it well against its pharma peers.
You may also be interested in...
Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.